［1］ ZHANG Y,RUMGAY H,LI M,et al.Nasopharyngeal cancer incidence and mortality in 185 countries in 2020 and the projected burden in 2040:population-based global epidemiological profiling［J］.JMIR Public Health Surveill,2023,9:e49968.
［2］ RUDIN CM,BRAMBILLA E,FAIVRE-FINN C,et al.Small-cell lung cancer［J］.Nat Rev Dis Primers,2021,7(1):3.
［3］ MICKE P，FALDUM A，METZ T，et al． Staging small cell lung cancer:veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease ［J］． Lung Cancer，2002，37(3):271－276．
［4］ YANG S,ZHANG Z,WANG Q.Emerging therapies for small cell lung cancer［J］.J Hematol Oncol,2019,12(1):47.
［5］ HORNBACK NB,EINHORN L,SHIDNIA H,et al.Oat cell carcinoma of the lung.Early treatment results of combination radiation therapy and chemotherapy［J］.Cancer,1976,37(6):2658-2664.
［6］ OTT PA,ELEZ E,HIRET S,et al.Pembrolizumab in patients with extensivestage small-cell lung cancer:results from the phase Ib KEYNOTE-028 study［J］.J Clin Oncol,2017,35(34):3823-3829.
［7］杜洋，范承娟，申维喜,等.非小细胞肺癌免疫治疗研究进展［J］.现代肿瘤医学，2021,29(13):2368-2371.
DU Yang,FAN Chengjuan,SHEN Weixi，et al.Progress in immunotherapy of non-small cell lung cancer［J］.Modern Oncology,2021,29(13):2368-2371.
［8］ RUDIN CM,AWAD MM,NAVARRO A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:randomized,double-blind,phase III KEYNOTE-604 study［J］.J Clin Oncol,2020,38(21):2369-2379.
［9］ CHO BC,YOH K,PERETS R,et al.Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab:safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer［J］.Lung Cancer,2021,159:162-170.
［10］ ANTONIA SJ,LOPEZ-MARTIN JA,BENDELL J,et al.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre,open-label,phase 1/2 trial［J］.Lancet Oncol,2016,17(7):883-895.
［11］ RECK M,SCHENKER M,LEE KH,et al.Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small cell lung cancer with high tumour mutational burden:patient-reported outcomes results from the randomised,open-label,phase Ⅲ CheckMate 227 trial［J］.Eur J Cancer,2019,116:137-147.
［12］ SPIGEL DR,VICENTE D,CIULEANU TE,et al.Second-line nivolumab in relapsed small-cell lung cancer:CheckMate 331［J］.Ann Oncol,2021,32(5):631-641.
［13］ OWONIKOKO TK,PARK K,GOVINDAN R,et al.Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer:CheckMate 451［J］.J Clin Oncol,2021,39(12):1349-1359.
［14］ LEAL T,WANG Y,DOWLATI A,et al.Randomized phase Ⅱ clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC):ECOG ACRINEA5161［J］.J Clin Oncol,2020,38(15):9000.
［15］ CHENG Y,HAN L,WU L,et al.Effect of first-line Serplulimab vs Placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer:The ASTRUM-005 randomized clinical trial［J］.JAMA,2022,328(12):1223-1232.
［16］ ISSAFRAS H,FAN S,TSENG CL,et al.Structural basis of HLX10 PD-1 receptor recognition,a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy［J］.PLoS One,2021,16(12):e0257972.
［17］ HORN L,MANSFIELD AS,SZCZESNA A,et al.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer［J］.N Engl J Med,2018,379(23):2220-2229.
［18］ LIU SV,RECK M,MANSFIELD AS,et al.Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab,carboplatin,and etoposide (IMpower133)［J］.J Clin Oncol,2021,39(6):619-630.
［19］ RECK M,HORN L,MOK TSK,et al.OA11.06 IMpower133:exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer［J］.J Thorac Oncol,2021,16(3):S128.
［20］ PUJOL J,GREILLIER L,AUDIGIER-VALETTE C,et al.A randomized noncomparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer:results from the IFCT-1603 trial［J］.J Thorac Oncol,2019,14(5):903-913.
［21］ PAZ-ARES L，DVORKIN M，CHEN Y，et al． Durvalumab plus platinumetoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):a randomised，controlled， open-label， phase 3 trial ［J］． Lancet，2019，394(10212):1929-1939．
［22］ GOLDMAN JW，DVORKIN M，CHEN YB，et al． Durvalumab，with or without tremelimumab，plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):updated results from a randomised,controlled，open-label,phase 3 trial［J］． Lancet Oncol，2021，22(1):51-65．
［23］ WANG J，ZHOU CC，YAO WX，et al． Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer( CAPSTONE-1):a multicentre，randomised， double-blind，placebo-controlled，phase 3 trial［J］． Lancet Oncol，2022，23( 6):739－747．
［24］ RECK M,BONDARENKO I,LUFT A,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small cell lung cancer:results from a randomized,double-blind,multicenter phase 2 trial［J］.Ann Oncol,2013,24(1):75-83.
［25］ RECK M,LUFT A,SZCZESNA A,et al.Phase III random ized tr ia l of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer［J］.J Clin Oncol,2016,34(31):3740-3748.
［26］ PAZ-ARES L,DVORKIN M,CHEN Y,et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):a randomised,controlled,open-label,phase 3 trial［J］.Lancet,2019,394(10212):1929-1939.
［27］ JOHNSON ML,CHO BC,LUFT A,et al.Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer:The phase III POSEIDON study［J］.J Clin Oncol,2023,41(6):1213-1222.
［28］ BONDARENKO I,JUAN-VIDAL O,PAJKOS G,et al.Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm a of the phaseⅡBALTIC study［J］.Ann Oncol,2018,29(8):596-602．
［29］ DHOLARIA B,HAMMOND W,SHREDERS A,et al.Emerging therapeutic agents for lung cancer［J］.J Hematol Oncol,2016,9(1):138．
［30］ SORDO-BAHAMONDE C,LORENZO-HERRERO S,GONZALEZ-RODRIGUEZ AP,et al.LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia［J］.Cancers (Basel),2021,13(9):2112.
［31］ SUN H,GAO W,PAN W,et al.Tim3+Foxp3+treg cells are potent inhibitors of effector T cells and are suppressed in rheumatoid arthritis［J］.Inflammation,2017,40(4):1342-1350.
［32］ HOMAYOUNI V,GANJALIKHANI-HAKEMI M,REZAEI A,et al.Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)［J］.Iran J Basic Med Sci,2016,19(11):1201-1208.
［33］ HARJUNPAA H,GUILLEREY C.TIGIT as an emerging immune checkpoint［J］.Clin Exp Immunol,2020,200(2):108-119.
［34］ YANG J,WANG L,BYRNES JR,et al.PVRL2 suppresses antitumor immunity through PVRIG-and TIGIT-independent pathways［J］.Cancer Immunol Res,2024,12(5):575-591.
［35］ YUAN L,TATINENI J,MAHONEY KM,et al.VISTA:A mediator of quiescence and a promising target in cancer immunotherapy［J］.Trends Immunol,2021,42(3):209-227.